Related Experiment Video
Updated: May 13, 2025
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
Published on: January 10, 2025
The Effect of Recombinant Human Brain Natriuretic Peptide Combined with Xinmailong on Heart Failure and Its Impact on
Zhaorui Ge1, Chunyan Li2, Yanling Liu3
1Department of Internal Medicine, Xianxian Hospital of Traditional Chinese Medicine, Xianxian, 062250, People's Republic of China.
Objective:
To analyze the effect of recombinant human brain natriuretic peptide (rhBNP) combined with Xinmailong on heart failure and its impact on cardiac function and inflammatory response.
Methods:
A retrospective analysis was conducted on the clinical data of 60 heart failure patients treated in our hospital from January 2023 to March 2024. The patients were included as research subjects to ensure the sample was representative. According to the different treatment methods, the patients were divided into two groups: the control group received only rhBNP treatment, and the experimental group received combined treatment with rhBNP and Xinmailong injection, with 30 patients in each group. The clinical effects, cardiac function, inflammatory response, and ventricular remodeling indicators of the two groups before and after treatment were observed and compared.
Results:
The total clinical effective rate of the experimental group was significantly higher than that of the control group (P<0.05). After treatment, the NT-proBNP level in the experimental group was significantly lower than that in the control group (P<0.05). After treatment, the levels of IL-6, TNF-α, and CRP in the experimental group were significantly lower than those in the control group (P<0.05). After treatment, the LVESD and LVEDD levels in the experimental group were significantly lower than those in the control group, while the LVEF level was higher in the experimental group than in the control group (P<0.05). There was no significant difference in the adverse event incidence between the two groups (P>0.05). The 6-minute walk test (6 MWT) level in the experimental group was significantly higher than in the control group (P<0.05).
Conclusion:
Recombinant human brain natriuretic peptide combined with Xinmailong is effective in treating heart failure, significantly improving cardiac function, reducing inflammatory responses, and reversing ventricular remodeling. It is also safe and beneficial for the patients' prognosis.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
01:26Heart Failure Drugs: Inotropic Agents
01:22Heart Failure Drugs: Diuretics
01:22Heart Failure Drugs: β-Blockers